Faisal Sadaf, Ivo Jessica, Patel Tejal
University of Waterloo School of Pharmacy, Kitchener.
Can Pharm J (Ott). 2021 Jul 30;154(5):312-323. doi: 10.1177/17151635211034198. eCollection 2021 Sep-Oct.
Smart medication adherence products (smart MAPs) capture and transmit real-time medication intake by using various means of connectivity, allowing for remote monitoring. Numerous such products with different features are available to address medication nonadherence. A comparison of the features of these products is needed for clinical decision-making. Therefore, the objective of this review was to compare smart MAPs available for in-home use.
We searched grey and published literature and videos to identify smart MAPs. To be considered smart, products required 2 features: connectivity (the ability for collected data to exist outside the physical device) and automaticity (the ability for data to be analyzed or processed automatically). Products were excluded if product descriptions were not available in English, not for in-home use and unable to dispense medications.
Of the 51 products identified, 38 commercially available and 13 prototypes met the definition. Of these, 75% ( = 38) contained alarms, 24% ( = 12) were unit-dose, 63% ( = 32) were multidose, 43% ( = 22) had locking features, 41% ( = 21) were portable and 88% ( = 45) sent notifications to patients. The cost of marketed products, excluding subscriptions, ranged from $10 to $1500 USD. Some products required a monthly ( = 16) or yearly ( = 1) subscription ranging from $10 to $100 USD.
There is a growing market of smart MAPs for in-home patient use with variable features. Clinicians can use these features to identify and recommend products according to the specific needs of their patients to address medication adherence. 2021;154:xx-xx.
智能药物依从性产品（智能MAPs）通过使用各种连接方式捕获并传输实时用药情况，实现远程监测。有许多具有不同功能的此类产品可用于解决药物不依从问题。临床决策需要对这些产品的功能进行比较。因此，本综述的目的是比较可供家庭使用的智能MAPs。
我们检索了灰色文献、已发表文献和视频，以识别智能MAPs。要被视为智能产品，需要具备两个功能：连接性（收集的数据能够在物理设备之外存在的能力）和自动化（数据能够自动分析或处理的能力）。如果产品描述没有英文版本、不是用于家庭使用或无法分发药物，则将其排除。
在识别出的51种产品中，38种商业产品和13种原型产品符合定义。其中，75%（n = 38）有警报功能，24%（n = 12）是单剂量的，63%（n = 32）是多剂量的，43%（n = 22）有锁定功能，41%（n = 21）是便携式的，88%（n = 45）会向患者发送通知。上市产品的成本（不包括订阅费用）从10美元到1500美元不等。一些产品需要每月（n = 16）或每年（n = 1）订阅，费用从10美元到100美元不等。
用于家庭患者的智能MAPs市场不断增长，其功能各异。临床医生可以根据患者的具体需求利用这些功能来识别和推荐产品，以解决药物依从性问题。2021；154：xx - xx。
